Venus Medtech (Hangzhou) Future Growth

Future criteria checks 2/6

Venus Medtech (Hangzhou) is forecast to grow revenue at 31.4% per annum. EPS is expected to grow by 62.5% per annum.

Key information

n/a

Earnings growth rate

62.5%

EPS growth rate

Medical Equipment earnings growth	17.1%
Revenue growth rate	31.4%
Future return on equity	n/a
Analyst coverage	Low
Last updated	21 Jun 2024

Recent future growth updates

No updates

Recent updates

Earnings and Revenue Growth Forecasts

OTCPK:VMTH.F - Analysts future estimates and past financials data (CNY Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2025	946	N/A	N/A	N/A	1
12/31/2024	735	-316	N/A	N/A	1
12/31/2023	491	-704	-873	-610	N/A
9/30/2023	472	-956	-856	-703	N/A
6/30/2023	452	-1,208	-839	-797	N/A
3/31/2023	429	-1,133	-874	-763	N/A
12/31/2022	406	-1,058	-908	-729	N/A
9/30/2022	397	-759	-845	-622	N/A
6/30/2022	387	-461	-781	-515	N/A
3/31/2022	401	-417	-670	-486	N/A
12/31/2021	416	-374	-559	-457	N/A
9/30/2021	415	-313	-505	-390	N/A
6/30/2021	413	-252	-452	-322	N/A
3/31/2021	345	-217	-406	-280	N/A
12/31/2020	276	-182	-361	-237	N/A
9/30/2020	252	-210	-333	-250	N/A
6/30/2020	228	-238	-305	-264	N/A
3/31/2020	231	-310	-316	-284	N/A
12/31/2019	233	-381	-328	-303	N/A
12/31/2018	115	-300	-178	-151	N/A
12/31/2017	18	-157	-102	-82	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if VMTH.F's forecast earnings growth is above the savings rate (2.4%).

Earnings vs Market: Insufficient data to determine if VMTH.F's earnings are forecast to grow faster than the US market

High Growth Earnings: Insufficient data to determine if VMTH.F's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: VMTH.F's revenue (31.4% per year) is forecast to grow faster than the US market (8.7% per year).

High Growth Revenue: VMTH.F's revenue (31.4% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if VMTH.F's Return on Equity is forecast to be high in 3 years time

Venus Medtech (Hangzhou) Future Growth

Future criteria checks 2/6

Key information

Recent future growth updates

Recent updates

Venus Medtech (Hangzhou) Inc. Appoints Bing Zhu as the Chief Financial Officer

Venus Medtech Venus-Vitae Completes First Two Implantations in SMART-ALIGN Pivotal Clinical Study

Venus Medtech (Hangzhou) Inc. Announces Supervisor and Supervisory Committee Changes

Venus Medtech (Hangzhou) Inc. to Report First Half, 2024 Results on Aug 30, 2024

Venus Medtech Venusp-Valve Completes First Implantation in Ide Pivotal Clinical Study in U.S

Venus Medtech (Hangzhou) Inc. to Report Fiscal Year 2023 Results on Mar 28, 2024

Venus Medtech (Hangzhou) Inc. Announces That Wan Yee Joseph Lau, an Independent Non-Executive Director, the Chairman of the Nomination Committee and A Member of Each of the Remuneration and Assessment Committee and the Audit Committee of the Board, Passed Away

Venus Medtech (Hangzhou) Inc. Appoints Fei Wang as the Chief Financial Officer

Venus Medtech (Hangzhou) Inc. Approves Mr. Liqiao Ma as an Executive Director

Venus Medtech (Hangzhou) Inc. Announces Executive Changes

Venus Medtech (Hangzhou) Inc. Announces Appointment of Mr. Lim Housen (Lin Haosheng) as Joint Chief Executive Officer with Effect from September 22, 2023

Venus Medtech (Hangzhou) Inc. to Report First Half, 2023 Results on Aug 31, 2023

Venus Medtech (Hangzhou) Inc., Annual General Meeting, Jun 30, 2023

Venus Medtech (Hangzhou) Inc. Announces Resignation of Haiyue Ma as Joint Company Secretary

Venus Medtech (Hangzhou) Inc. Announces Board Changes

Venus Medtech (Hangzhou) Inc. Announces Resignation of Lim Hou-Sen as an Executive Director and Nisa Bernice Wing-Yu Leung as Non-Executive Director and Vice Chairwoman

Venus Medtech (Hangzhou) Inc. Announces Change of Employee Representative Supervisor and Chairperson of the Supervisory Committee

Venus Medtech (Hangzhou) Inc. Announces Change of Employee Representative Supervisor and Chairperson of the Supervisory Committee

Venus Medtech (Hangzhou) Inc. to Report First Half, 2022 Results on Aug 31, 2022

China's National Medical Products Administration Approves Venusp-Valve, Venus Medtech's In-House Developed Innovative Transcatheter Pulmonic Valve Replacement System

Venus Medtech (Hangzhou) Inc. Announces First American Patient Treated with VenusP-Valve Under Compassionate Use

Venus Medtech (Hangzhou) Inc. Announces Expandable Bioprosthetic Dry Tissue Valve Venus-Neo Completed First Clinical Application

Venus Medtech (Hangzhou) Inc., Annual General Meeting, May 30, 2022

Venus Medtech (Hangzhou) Inc. to Report Fiscal Year 2021 Results on Mar 31, 2022

Venus Medtech (Hangzhou) Inc. Appoints Amir Gross as Head of Venus Global Heart Valve Innovation Center

Venus Medtech (Hangzhou) Inc. Announces Completion of Global First Clinical Application of Venus-Powerx

Venus Medtech (Hangzhou) Inc. Announces Venus Vitae, Balloon-Expandable Dry Tissue Tavr System Successfully Completed the First Two Implantations in the Fim Clinical Trial

Venus Medtech (Hangzhou) Inc. (SEHK:2500) commences an Equity Buyback Plan for 43,170,744 shares, representing 9.79% of its issued share capital, under the authorization approved on May 21, 2021.

Venus Medtech (Hangzhou) Inc. to Report Fiscal Year 2020 Results on Mar 31, 2021

Venus Medtech (Hangzhou) Inc. has completed a Follow-on Equity Offering in the amount of HKD 1.444843 billion.

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies